2021.12.27
On December 23, 2021, Shanghai Bio-heart Biological Technology Co., Ltd. (“Bioheart” or the “Company”) offered 23,937,000 H shares globally at the price of HK$ 21.25 per share and was successfully listed on the Hong Kong Stock Exchange.
Bioheart is a leading manufacturer of interventional cardiovascular devices in China. It focuses on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN) to address the medical needs of Chinese patients in the treatment of coronary and peripheral artery disease and uncontrolled hypertension. JunHe acted as the IP lawyer for Bioheart when the Company was preparing for the IPO and assisted it in carrying out IP due diligence. JunHe provided quality, rigorous and effective legal services and helped the Company identify the risks associated with patent-related intellectual property.
The IP due diligence conducted for the IPO of Bioheart involved not only a comprehensive analysis of the intellectual property owned by the Company, but also a FTO analysis on the Company’s core products both in China and in some foreign countries. Through clear communication and cooperation with foreign law firms, JunHe successfully helped the Company identify and prevent patent-related risks associated with its core products in certain regions. JunHe was unanimously affirmed and highly trusted by the Company due to the team’s thorough work and professional services.
The leading partners of this project were Dr. WANG, Zhaohui (Zoe) , CHEN, Jiang (Joe) and MAO, Jian .
